Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High-cost treatments for advanced lung cancer in Japan (Lung Cancer Study Group of the Japan Clinical Oncology Group).

Japanese journal of clinical oncology - 3 Oct 2024

Watanabe Kageaki, Sasaki Keita, Machida Ryunosuke, Shimizu Junichi, Yamane Yuki, Tamiya Motohiro, Saito Shin, Takada Yuji, Yoh Kiyotaka, Yoshioka Hiroshige, Murakami Haruyasu, Kitazono Satoru, Goto Yasuhiro, Horinouchi Hidehito, Ohe Yuichiro

Abstract excerpt

BACKGROUND: The treatment of lung cancer has made dramatic progress in the past decade, but due to the high cost of drugs, the total pharmaceutical cost has been rising explosively. There are currently no data available in Japan on which regimens are used, to what extent they are used, and what their total cost is. METHODS: Sixty Japanese centers belonging to the Lung Cancer Study Group of the Japan Clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Costs

Share to ErbB Receptors

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to Small Cell Lung Carcinoma

Source

Identifiers

PMID: 39158350
DOI: 10.1093/jjco/hyae094

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High-cost treatments for advanced lung cancer in Japan (Lung Cancer Study Group of the Japan Clinical Oncology Group).PMID 39158350Read ↗

Does pathologic type shape the hospitalization costs of advanced non- small cell lung cancer patients? A multicenter real-world data studySemantic proximity Read ↗

Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review.Semantic proximity Read ↗

A systematic review and meta-analysis on effectiveness and safety of traditional Chinese medicine combined with EGFR-TKIs in treating advanced non-small cell lung cancerSemantic proximity Read ↗

Cost-effectiveness of osimertinib in the treatment of advanced EGFR-mutated non-small cell lung cancer: a systematic review.Semantic proximity Read ↗

Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review.Semantic proximity Read ↗

Cost-effectiveness of adjuvant icotinib versus chemotherapy for patients with stage II-IIIA EGFR-mutated non-small cell lung cancer in China.Semantic proximity Read ↗

Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients.Semantic proximity Read ↗

Treatment patterns in advanced/metastatic non-small-cell lung cancer in China: results from the CancerMPact® survey 2021.Semantic proximity Read ↗

Trial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China.Semantic proximity Read ↗

Oncological therapy in stage IV lung cancer patients at the end-of-life – A retrospective single-center cohort analysis in the era of tyrosine kinase inhibition and immunotherapySemantic proximity Read ↗

Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.Semantic proximity Read ↗

Nivolumab plus ipilimumab for elderly Chinese patients with advanced non-small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.